Taisho Pharmaceutical Co., Ltd.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Employees: 5.6K

Market Cap: -

Website: http://www.taisho.co.jp

Clinical Trials

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: TS-142
Drug: Moxifloxacin

First Posted Date: 2021-05-05

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 59

Registration Number: NCT04873323

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku, Japan

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: [14C] TS-142

First Posted Date: 2021-03-24

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT04814771

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Phase 1

Completed

Conditions: Patients With Mild Obstructive Sleep Apnea Hypopnea

Interventions: Drug: TS-142
Drug: Dose-matched Placebo to TS-142

First Posted Date: 2021-02-09

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 46

Registration Number: NCT04746105

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: TS-142
Drug: Zopiclone
Drug: Placebo

First Posted Date: 2021-01-06

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 61

Registration Number: NCT04696952

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: TS-091

First Posted Date: 2020-11-17

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT04631276

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Phase 2

Completed

Conditions: Insomnia Disorder

Interventions: Drug: TS-142
Drug: Dose-matched Placebo to TS-142

First Posted Date: 2020-10-05

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04573725

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: TS-142
Drug: Itraconazole

First Posted Date: 2020-09-21

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT04557163

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Late Phase II Study of TS-142 in Patients With Insomnia

Phase 2

Completed

Conditions: Patients With Insomnia

Interventions: Drug: TS-142

First Posted Date: 2020-07-13

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 179

Registration Number: NCT04469023

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: TS-142, 10 mg
Drug: TS-142, 20 mg
Drug: TS-142, 30 mg

First Posted Date: 2019-11-20

Last Posted Date: 2023-10-26

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04169906

Locations: 🇯🇵
The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo (fasting)
Drug: Placebo (feeding)
Drug: 1 mg of TS-142
Drug: 10 mg of TS-142 (feeding)
Drug: 3 mg of TS-142
Drug: 10 mg of TS-142 (fasting)
Drug: 30 mg of TS-142

First Posted Date: 2019-11-20

Last Posted Date: 2023-10-26

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT04169893

Locations: 🇯🇵
The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy